Entrada Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
TRDA$4.89+7.5%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Report of Ernst & Young LLP, Independent Registered Public Accounting Firm (PCAOB ID: 42) | 137 |
|---|---|
| Consolidated Balance Sheets | 138 |
| Consolidated Statements of Operations and Comprehensive Loss | 139 |
| Consolidated Statements of Stockholders’ Equity | 140 |
| Consolidated Statements of Cash Flows | 141 |
| Notes to Consolidated Financial Statements | 143 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.